Kaplan-Meier curves for PFS, EFS∗, and DOCR in efficacy-evaluable patients. ∗Events consisted of 8 instances of PD, 5 deaths, and 3 instances of nonstudy next antilymphoma therapy (NALT) being introduced. Of the NALT events, 2 occurred because of AEs leading to early study treatment discontinuation (and subsequent transition to R-CHOP therapy), and 1 NALT event occurred when prophylactic systemic methotrexate was administered in violation of the protocol.